Cosentyx Injection
Product Images NDC 0078-1056

Product Visual Gallery

This gallery contains 48 technical images submitted to the FDA as part of the official labeling for Cosentyx (NDC 0078-1056). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel Ndc 0078-0639-97 Cosentyx® (secukinumab) Injection Single-use Prefilled Syringe 150 mg/ml 1 Prefilled Syringe Attention: Dispense With Enclosed Medication Guide. For Subcutaneous Use Only Sterile Solution (Contains No Preservative Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Rx only NOVARTIS)

COSENTYX 150 mg/mL injection in a single-dose prefilled syringe packaging label. The product contains secukinumab for subcutaneous use. Manufactured and distributed by Novartis Pharmaceuticals Corporation. The carton includes one prefilled syringe, prescribing information, and medication guide. The label features storage instructions and cautionary statements about natural rubber latex allergy risk.*

FDA Label Image

Figure A (Cosentyx 02)

Instructional illustration showing two hands preparing a syringe by attaching or removing a needle cap. The downward arrow emphasizes the motion of pressing or securing the needle onto the syringe, demonstrating part of the medication preparation process for subcutaneous injection.*

FDA Label Image

Figure B (Cosentyx 03)

Illustration showing a hand holding a vial stopper with a central opening, likely demonstrating how to access or insert a syringe needle into a vial, related to injection preparation procedures.*

FDA Label Image

Figure C (Cosentyx 04)

An instructional illustration showing a hand holding a syringe-like device for subcutaneous injection. The illustration depicts the user's hand pulling a cap or cover off the injection device, indicated by an upward-pointing arrow. No text or branding is visible in the image.*

FDA Label Image

Figure D (Cosentyx 05)

An instructional illustration showing two hands preparing a syringe for injection. One hand holds the syringe vertically while the other is positioned near the top, likely to remove an air bubble before subcutaneous administration.*

FDA Label Image

Figure E (Cosentyx 06)

Illustration showing two subcutaneous injection syringes, one with the needle shield on and one with the needle exposed. The syringes are marked with measurement graduations for dosing.*

FDA Label Image

Figure F (Cosentyx 07)

Illustration showing common subcutaneous injection sites on the human body, including upper arm, abdomen, front of thighs, and upper buttocks areas.*

FDA Label Image

Cosentyx Prefilled Syringe Parts (see Figure A): (Cosentyx 08)

An instructional diagram of a subcutaneous injection syringe for COSENTYX (secukinumab). The illustration labels parts including the needle cap, syringe guard, viewing window with label and expiration date, finger grips, syringe guard wings, plunger, and plunger head.*

FDA Label Image

Figure B (Cosentyx 09)

An instructional illustration showing three items arranged in sequence for injection preparation or disposal: a wipe or alcohol prep pad on the left, a round cotton ball or gauze in the center, and a sharps disposal container on the right labeled 'SHARPS.' This likely depicts steps involved in safely administering and disposing of a subcutaneous injection, such as Cosentyx.*

FDA Label Image

Figure C (Cosentyx 10)

An illustration showing a human figure with shaded areas indicating preferred subcutaneous injection sites. The highlighted regions include the abdomen around the navel and the front of both thighs.*

FDA Label Image

Figure D (Cosentyx 11)

An anatomical illustration showing the back view of a human figure with shaded areas on both upper arms, indicating possible injection sites for a subcutaneous injection.*

FDA Label Image

Figure E (Cosentyx 12)

An instructional illustration showing a hand holding a syringe with the needle cap being removed by pulling it off. The image demonstrates how to prepare the syringe for injection by removing the protective needle cover.*

FDA Label Image

Figure F (Cosentyx 13)

An instructional illustration showing a hand holding a syringe at a 45-degree angle, approaching the skin of another person's finger for subcutaneous injection. The diagram emphasizes proper injection angle technique for administration of an injectable drug.*

FDA Label Image

Figure G (Cosentyx 14)

An instructional diagram showing the proper grip and positioning of a COSENTYX (secukinumab) injection device for subcutaneous administration. The illustration includes a close-up insert highlighting the needle guard or cap area to emphasize safe handling before injection.*

FDA Label Image

Figure H (Cosentyx 15)

Instructional illustration showing a hand holding a syringe injection device, demonstrating the removal of the needle cap by pulling it off.*

FDA Label Image

Figure I (Cosentyx 16)

An instructional illustration showing a hand holding a syringe with the thumb and forefinger, positioned to possibly remove a cap or prepare the injection. The syringe is intended for subcutaneous injection of COSENTYX (secukinumab).*

FDA Label Image

Figure J (Cosentyx 17)

An illustration showing a hand disposing of a subcutaneous injection syringe into a container labeled "SHARPS." The image is related to safe disposal procedures for injectable products such as COSENTYX (secukinumab).*

FDA Label Image

Figure A (Cosentyx 18)

Illustration of a COSENTYX prefilled syringe injection, showing labeled components including the needle, needle guard, cap, viewing window, and internal needle cover. The syringe is intended for subcutaneous injection of secukinumab by Novartis Pharmaceuticals Corporation.*

FDA Label Image

Figure B (Cosentyx 19)

Illustration of a single dose prefilled injection pen for COSENTYX, a subcutaneous injection of secukinumab. The pen is shown with a protective cap on the needle end, designed for patient self-administration or use by healthcare professionals.*

FDA Label Image

Figure C (Cosentyx 20)

An instructional illustration showing a sequence involving three items: a wipe packet, followed by a circular pad or swab, and ending with a sharps disposal container. The icons suggest steps related to injection site preparation and safe needle disposal, commonly associated with subcutaneous injection usage.*

FDA Label Image

Figure D (Cosentyx 21)

An instructional diagram of a subcutaneous injection device for COSENTYX (secukinumab) showing a viewing window and the medication expiration (EXP) area on the pen. The image highlights the external features of the injection pen used for administering secukinumab.*

FDA Label Image

Figure E (Cosentyx 22)

An instructional diagram showing shaded areas on the front of a male torso and upper legs, indicating recommended subcutaneous injection sites for COSENTYX (secukinumab) injection. The shaded areas include the abdomen below the navel and the front of both thighs.*

FDA Label Image

Figure F (Cosentyx 23)

Illustration showing preferred subcutaneous injection sites on the outer upper arms of a human body, relevant for administering COSENTYX (secukinumab) injection.*

FDA Label Image

Figure G (Cosentyx 24)

An instructional diagram showing a person administering a subcutaneous injection into the thigh. The illustration highlights the hand holding the injection device with arrows indicating a shaking or tapping motion on the injection site before or during administration.*

FDA Label Image

Figure H (Cosentyx 25)

An instructional illustration showing how to attach a needle to a syringe or injection device by aligning and connecting the two components. The image depicts hands holding each part, with an arrow indicating the direction to connect them.*

FDA Label Image

Holding Your Cosentyx Sensoready Pen: (Cosentyx 26)

Illustration showing the correct and incorrect way to hold a pen-style injection device for subcutaneous injection. The correct position shows the device held vertically, while the incorrect position shows it angled. This ensures proper administration technique for COSENTYX (secukinumab) injection.*

FDA Label Image

Figure I (Cosentyx 27)

Illustration showing a hand holding a prefilled injection syringe upright with the needle end pointing downward, demonstrating the proper grip technique for a subcutaneous injection device.*

FDA Label Image

Figure J (Cosentyx 28)

Instructional illustration showing a hand holding an injection device poised for subcutaneous administration. An arrow points downward indicating the direction to press or inject the medication into the skin, demonstrating part of the injection process for a subcutaneous dosage form.*

FDA Label Image

Figure K (Cosentyx 29)

An instructional illustration showing a hand holding and pressing down a syringe with a green plunger, positioned perpendicularly against the injection site, indicating the technique for administering a subcutaneous injection.*

FDA Label Image

Figure L (Cosentyx 30)

An instructional illustration showing a hand holding a syringe-like injection device, likely demonstrating the preparation or administration of a subcutaneous injection. The device contains a visible liquid inside the barrel.*

FDA Label Image

Figure M (Cosentyx 31)

An instructional illustration showing a single-use injection pen being disposed of into a sharps container labeled 'SHARPS'. The arrow indicates the direction for safely discarding the injection device after use.*

FDA Label Image

Figure 4: Asas40 Responses In Nr-axspa1 Study Over Time Up To Week 16 (Cosentyx 32)

A line graph showing the percentage of responders over time (weeks) for three groups: Cosentyx 150 mg Load, Cosentyx 150 mg No Load, and Placebo. The graph displays response rates from 0 to 16 weeks, with Cosentyx treatment groups showing higher responder percentages compared to placebo over time.*

FDA Label Image

Principal Display Panel Ndc 0078-1056-97 Cosentyx® (secukinumab) Injection 75 mg/0.5 mL 1 Single-dose Prefilled Syringe For Subcutaneous Use Only Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Attention: Dispense With Enclosed Medication Guide. Novartis (Cosentyx 33)

Box packaging label for COSENTYX (secukinumab) Injection, 75 mg/0.5 mL in a single-dose prefilled syringe. The label indicates subcutaneous use only and contains cautions about natural rubber latex. Manufactured by Novartis Pharmaceuticals Corporation, the packaging also features dosage storage instructions, ingredient details, and includes a barcode and NDC number 0078-1056-97.*

FDA Label Image

Figure 1: Percent Of Patients Achieving Acr 20 Responsea In Psa1 Study Through Week 24 (Cosentyx 34)

Line graph showing percent of responders over time (weeks) comparing Cosentyx 150 mg, Cosentyx 300 mg, and placebo groups. The x-axis represents time in weeks up to 24, and the y-axis shows percent of responders from 0 to 100. Cosentyx 150 mg and 300 mg exhibit increasing response rates, peaking around 60 percent, while placebo remains below 30 percent throughout.*

FDA Label Image

Figure 2: Asas20 Responses In All As1 Study Patients Over Time Up To Week 16 (Cosentyx 35)

A line graph comparing the percent of responders over 16 weeks between Cosentyx 150 mg and placebo groups. The X-axis represents time in weeks from 0 to 16, while the Y-axis shows the percent of responders from 0 to 100. The graph shows increasing response rates over time with a higher response in the Cosentyx 150 mg group compared to placebo.*

FDA Label Image

Figure 3: Asas20 Responses In All As3 Study Patients Over Time Up To Week 16 (Cosentyx 36)

A line graph showing the percent of responders over 16 weeks for three groups: Cosentyx 150 mg with IV loading, Cosentyx 300 mg with IV loading, and placebo. The x-axis represents time in weeks, and the y-axis shows the percent of responders. Both Cosentyx groups show a higher percentage of responders compared to placebo throughout the period.*

FDA Label Image

Cosentyx Prefilled Syringe Parts (see Figure A): (Cosentyx 37)

An instructional diagram showing the labeled parts of a subcutaneous injection syringe, including needle cap, syringe guard, view window with label & expiration date, finger grips, syringe guard wings, plunger, and plunger head.*

FDA Label Image

Figure B (Cosentyx 38)

An instructional illustration showing three items for an injection procedure: a wipe, a cotton ball or gauze pad, and a sharps disposal container labeled 'SHARPS' for safe needle disposal.*

FDA Label Image

Figure C (Cosentyx 39)

An anatomical illustration showing recommended subcutaneous injection sites on a human body. The shaded areas include the lower abdomen and the front upper thighs, indicating locations suitable for subcutaneous injection administration.*

FDA Label Image

Figure D (Cosentyx 40)

An anatomical illustration of a human figure from the back, highlighting both upper arms with shaded areas. The image depicts recommended subcutaneous injection sites in both upper arm regions, useful for administering medications such as COSENTYX (secukinumab) injection.*

FDA Label Image

Figure E (Cosentyx 41)

An instructional illustration showing a hand holding a syringe labeled COSENTYX (secukinumab) injection, with the other hand pulling off the needle cap from the syringe prior to administration. The image focuses on safe preparation for subcutaneous injection.*

FDA Label Image

Figure F (Cosentyx 42)

An instructional illustration depicting a hand administering a subcutaneous injection with a syringe at a 45-degree angle to the skin, demonstrating proper injection technique for COSENTYX (secukinumab). The image shows one hand holding the syringe and the other stabilizing the skin for injection.*

FDA Label Image

Figure G (Cosentyx 43)

An instructional diagram showing a person holding a prefilled injection device, preparing to administer a subcutaneous injection. The image highlights the positioning of the fingers near the needle guard with a close-up view of the safety mechanism on the injector tip.*

FDA Label Image

Figure H (Cosentyx 44)

An instructional line drawing showing a hand holding a subcutaneous injection device, likely a syringe or autoinjector pen, poised for use. One finger pushes a button or plunger at the top while the needle end points downward, illustrating the injection technique for a drug such as secukinumab.*

FDA Label Image

Figure I (Cosentyx 45)

An instructional illustration showing a hand removing the needle cap from a prefilled injection device, presumably for the subcutaneous administration of the medication. The diagram highlights the proper grip and motion to safely remove the cap before injection.*

FDA Label Image

Figure J (Cosentyx 46)

An instructional illustration showing a hand disposing of a used syringe into a container labeled 'SHARPS.' The image demonstrates safe needle disposal typically associated with subcutaneous injection products like COSENTYX (secukinumab).*

FDA Label Image

Cosentyx 47

A Kaplan-Meier curve chart showing the proportion of patients with disease flare (%) over time in days, comparing Cosentyx (secukinumab) with placebo in Part 2. The graph displays two lines: a solid line for Cosentyx and a dashed line for placebo, with censored data indicated by plus signs. Below the graph, a table shows the number of patients at risk for both Cosentyx and placebo over time.*

FDA Label Image

Cosentyx 48

A Kaplan-Meier curve comparing the proportion of patients with disease flare (%) over time (days) between Cosentyx and placebo in Part 2 of a clinical study. The graph shows two survival curves: one solid line for Cosentyx, and a dotted line for placebo, with censored data points marked by crosses. Below the graph, a table indicates the number of patients at risk at various time points for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.